Sana Biotechnology, Inc.: Business Overview, Financials & Competitive Analysis
Sana Biotechnology, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Hypoimmune cell therapy leader with validated clinical proof-of-concept in type 1 diabetes, strong analyst support, and capital runway to advance lead programs through 2026 IND filings. Analysts rate SANA a strong buy with 8 analysts recommending buy and 12-month price targets around $7.83-$8.71, implying significant upside. The company has.
What is Sana Biotechnology, Inc.'s industry? Sana Biotechnology, Inc. (sana.com) operates in Biotechnology - Cell & Gene Therapy. AskCyborg classifies Sana Biotechnology, Inc. under Biotechnology - Cell & Gene Therapy in its company registry.
Sana Biotechnology is a biotechnology company focused on utilizing engineered cells as medicines, developing ex vivo and in vivo cell engineering platforms for therapeutic areas including type 1 diabetes, B cell media...
Cyborg Score thesis
Hypoimmune cell therapy leader with validated clinical proof-of-concept in type 1 diabetes, strong analyst support, and capital...
Read the full analyst-debate transcript →Get the Latest Sana Biotechnology, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSana Biotechnology, Inc. Overview
Pro stress-test →Sana Biotechnology is a biotechnology company focused on utilizing engineered cells as medicines, developing ex vivo and in vivo cell engineering platforms for therapeutic areas including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company represents an emerging player in regenerative medicine with potential to address significant unmet medical needs.
Strategic Profile
Pro stress-test →The company achieved a major validation milestone with positive 12-week clinical data for UP421 showing transplanted HIP-modified islet cells survived immune detection and produced C-peptide without immunosuppression, published in NEJM. Sana has strategically reprioritized focus toward SC451 for type 1 diabetes and SG293 for B-cell disease, suspending its allogeneic CAR T programs to concentrate resources.
Competitive Landscape
Pro stress-test →Caribou Biosciences is noted as a major competitor in engineered cell therapy. Sana competes in the broader cell and gene therapy space against larger players including CRISPR/gene editing companies (Beam Therapeutics, Editas) and CAR-T developers (Juno, Kite). Sana has partnered with Beam Therapeutics for CRISPR Cas12b technology and Harvard College for hypoimmune cell IP, differentiating its approach through multi-platform positioning.
Industry Context
Sana Biotechnology, Inc. operates in Biotechnology - Cell & Gene Therapy.
Key facts
Founded: 2018 · Headquarters: Seattle, WA · Employees: 414 · Market cap: $1.08B